XTLB | tickerfilter.com

Fundamental analysis

19%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 10%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.54%

1 Month

-7.79%

3 Months

-43.75%

6 Months

-49.32%

1 Year

-64.29%

2 Year

-12.11%

Key data

Stock price

$1.12

P/E Ratio

0.00

DAY RANGE

$1.05 - $1.23

EPS

N/A

52 WEEK RANGE

$0.92 - $3.13

52 WEEK CHANGE

-$64.62

MARKET CAP

15.203 M

YIELD

N/A

SHARES OUTSTANDING

5.449 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.58

PUBLIC FLOAT

AVERAGE 10 VOLUME

$5,585

AVERAGE 30 VOLUME

$5,542

Company detail

CEO: Shlomo S. Shalev
Region: US
Website: xtlbio.com
Employees: 8
IPO year: 2005

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.

XTL Names Mr. Noam Band as its New Chief Executive Officer

Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company’s new Chief Executive Officer. Shlomo Shalev will continue as the Chairman of the Board of Directors. Previously, Mr. Band has served as the Chairman and Chief Executive Officer of Gix Internet Ltd. (formerly Algomizer Ltd.) (TASE:GIX), a publicl

XTLB - XTL BIOPHARMACEUTICALS LTD

XTL Names Mr. Noam Band as its New Chief Executive Officer